Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.46 |
| ▸ | VDR | P11473 | 2/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | GYS1 | P13807 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1482082 | 0.92 | NR1H4 (0.51) | NR1H4VDRPTGER4ALOX5DRD2 | |
| SCHEMBL1482456 | 0.92 | MRGPRX4 (0.49) | NR1H4MRGPRX4VDR | |
| SCHEMBL1482458 | 0.88 | PTGER1 (0.43) | NR1H4MRGPRX4DRD2TBXA2RTHRB | |
| SCHEMBL1482477 | 0.86 | NR1H4 (0.49) | NR1H4VDRPTGER4ALOX5DRD2 | |
| SCHEMBL1482639 | 0.86 | NR1H4 (0.49) | NR1H4VDRALOX5 | |
| SCHEMBL1483014 | 0.85 | NR1H4 (0.51) | NR1H4MRGPRX4VDRALOX5 | |
| SCHEMBL1483074 | 0.84 | NR1H4 (0.49) | NR1H4VDRALOX5 | |
| SCHEMBL1482797 | 0.83 | MRGPRX4 (0.43) | NR1H4MRGPRX4VDRALOX5CD274 | |
| SCHEMBL1483039 | 0.83 | NR1H4 (0.49) | NR1H4VDRALOX5 | |
| SCHEMBL1482376 | 0.82 | DRD2 (0.47) | NR1H4DRD2TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| EP-2483247-A1 | NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011039130-A1 | NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-07 | — | — | WO | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | BRI3BP, CYP3A4, RB1 | NR1H4 776/4885MRGPRX4 650/4885VDR 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.